Hi Kagestarr.
I'm more like a visitor and observer here.
Once in while I offer my 2 cents worth- of usually alternative knowledge.
In regards to the new MS diagnostic criteria presented by the International Panel on Diagnosis of MS.
Potential Conflicts of Interest:
C.H.P.: consultancy, Actelion, Biogen Idec, Bayer Schering, Teva, Merck-Serono, Novartis, Glaxo SK, UCB, Roche, Antisense Ther; expert testimony, Biogen Idec; grants/grants pending, Biogen Idec, Bayer Schering, Teva, Merck-Serono, Novartis, Glaxo SK, UCB. S.C.R.: travel support, US NMSS, ECTRIMS, Multiple Sclerosis International Federation, MS Ireland; payment for writing or reviewing manuscript, US NMSS, ECTRIMS; consultancy, US NMSS, ECTRIMS, Sanofi-Aventis, Bayer Schering Pharma, BioMarin, EMD Merck Serono, Mt Sinai College of Medicine (New York, NY), European Committee for Treatment and Research in MS, Eisai, INC Research, Eli Lilly Inc, Isis Pharmaceuticals Inc, MediciNova, Cleveland Clinic Foundation, Free University Amsterdam, Genentech/F. Hoffmann-LaRoche, Synthon BV, Antisense Therapeutics Ltd, BaroFold, Protein Design Laboratories; royalties, Demos Medical Publishers (New York, NY). B.B.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; consultancy, Biogen Idec, Genzyme; grants/grants pending, Multiple Sclerosis Society of Canada, Canadian Institutes of Health Research; paid educational presentations, honoraria for symposia at the American Academy of Neurology. M.C.: board membership, GENMAB; consultancy, Biogen, Genzyme; grants/grants pending, Bayer Schering, Biogen Elan, Novartis, Merck Serono, Sanofi-Aventis, Teva. J.A.C.: travel expenses, US NMSS; consultancy, Biogen Idec, Lilly, Novartis, Serono, Teva; grants/grants pending, Department of Defense, NIH, US NMSS; speaking fees, Biogen Idec, Novartis, Sanofi-Aventis, Waterfront Media. M.F.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, Teva Pharmaceutical Industries Ltd, Genmab A/S; consultancy, Bayer Schering Pharma, Biogen-Dompé AG, Genmab A/S, Merck Serono, Pepgen Corporation, Teva Pharmaceutical Industries Ltd; grants/grants pending, Bayer-Schering, Biogen-Dompé AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd, Fondazione Italiana Sclerosi Multipla, Fondazione Mariani; speaking fees, Bayer Schering Pharma, Biogen-Dompé AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd; travel expenses, Teva, Biogen-Dompé AG, Merck-Serono, Sanofi-Aventis, Genmab, Bayer Schering. K.F.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; consultancy, Bayer Schering Pharma, Biogen Idec, Merck Serono; grants/grants pending, Bayer Schering Pharma, Biogen Idec, Asahi Kasei Kuraray Medical Co Ltd, Chemo-Sero-Therapeutic Research Institute, Mitsubishi Tanabe Pharma, Teijin Pharma, Theva Pharmaceutical, Eisai Inc, Kowa Pharmaceutical, Ministry of Education, Science, and Technology of Japan, Ministry of Health, Labor, and Welfare of Japan; speaking fees, Bayer Schering Pharma, Biogen Idec, Eisai Inc, Mitsubishi Tanabe Pharma, Astellas Pharma, Takeda Pharmaceutical Company Ltd, Asahi Kasei Kuraray Medical Co; paid manuscript preparation, Cosmic Corporation; royalties, Bunkodo. E.H.: travel expenses, US NMSS, ECTRIMS, MSIF, MS Ireland; consultancy, Biogen Idec, Genzyme, Merck Serono, Novartis, Grifols; grants/grants pending, Biogen Idec; speaking fees, Biogen Idec, Genzyme, Merck Serono, Novartis, Bayer Healthcare, Sanofi-Aventis; paid educational presentations, Novartis. M.H.: consultancy, Biogen Idec; grant/grants pending, Health Research Board Ireland; speaking fees, Biogen Idec. L.K.: travel expenses, US NMSS; board membership, Editorial Board of Multiple Sclerosis; grants/grants pending, National Research Foundation Switzerland, Rubatto Foundation, Swiss MS society, European Union, Roche Foundation, Novartis Foundation; speaking fees, various companies involved in development of MS therapeutics; paid educational presentations, Neurostatus System for Standardized Neurological Assessment. F.D.L.: travel support, US NMSS; consultancy, Novartis, Bayer, Biogen Idec, EMD Serono, Genentech, Teva Neuroscience, Genmab, Medicinova, Actelion, Allozyne, Sanofi-Aventis, Acorda, Questcor, Avanir, Roche, Celgene, Abbott, Pfizer, Morphosys; grants/grants pending, NIH, NMSS, Acorda, Biogen Idec, Teva, Novartis, Sanofi-Aventis; speaking fees, Genzyme, Teva, EMD Serono; paid educational presentations, various continuing medical education services; stock/stock options, cognition pharmaceuticals. X.M.: travel expenses, US NMSS; consultancy, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Almirall; grants/grants pending, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Almirall; speaking fees, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Almirall. M.S.-W.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; fees for review activities, Genentech, Merck Serono, Roche; board membership, Board of Directors of Active Biotech, Sweden; consultancy, Elan, Merck Serono; speaking fees, Bayer Health Care, Merck Serono, Serono Symposia International Foundation, Sanofi-Aventis, Swedish Bank SEB. A.J.T.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, National Hospital Development Foundation, Patrick Berthoud Charitable Trust; consultancy, Weleda AG/Society for Clinical Research, Medical Research Council, MS Society of Great Britain, Merck Serono, Biogen Idec, DIGNA Biotech, Novartis, Eisai London Research Laboratories, Teva Pharmaceuticals; grants/grants pending, National Institute for Health Research, MS Society of Great Britain; speaking fees, Serono Symposia, Sanofi-Aventis; travel expenses, MS International Federation, US NMSS, Biogen Idec; honoraria, Editor-in-Chief of Multiple Sclerosis. E.W.: consultancy, Roche, Actelion; grants/grants pending, US NMSS, NIH; speaking fees, Teva; received free drug for a trial given by Sanofi-Aventis and Biogen Idec. B.W.: travel support, US NMSS; European Committee for Treatment of MS; MS International Foundation; MS Ireland; consultancy, Novartis, Biogen Idec; employment, Mayo Clinic; royalties, RSR Ltd. J.S.W.: travel support, US NMSS, ECTRIMS, MSIF, MS Ireland; board membership, Antisense Therapeutics Ltd, BCDecker, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Pharmaceuticals, Eli Lilly, UCB; consultancy, Genentech, Novartis Pharmaceuticals, Sanofi-Aventis, Teva Neuroscience, Teva Pharmaceuticals, Acorda, Acetilon, Bayer HealthCare, Facet Biotech, Peptimmune; grants/grants pending, NIH, Sanofi-Aventis, Clayton Foundation for Research, US NMSS; honoraria for lectures, Consortium MS Centers, Sanofi-Aventis New Zealand, Sterling Meeting Services, USF Health Professionals, Texas Neurological Society, Teva Pharmaceuticals, Lone Star Chapter NMSS, ICHE, Pfizer EMD Serono, SUNY, Stony Brook Foundation, UTMB, Medscape CME, University of Buffalo, Serono Symposia International Foundation, University of Utah; royalties, Millipore (Chemicon International) Corporation.
Makes you think. Right?
What if established MS dx and treatments have NOTHING to do with the truth.
Ever wonder? I do - quite often, as a matter of fact.
Cheers!
Niko